ERS Congress 2025: highlights from the Paediatrics Assembly Authors: Deepa Patel, Shahriyar Shahbazi Khamas, Pia Maier, Refika Ersu, Alexander Moeller, Susanne J.H. Vijverberg Published: 2026 ABSTRACT Shareable abstract#ERSCongress 2025: surge in youth #vaping, new evidence on exposome-driven risks, advances in rare paediatric lung diseases. Strong global collaboration remains essential to support low-resource settings and reduce growing respiratory #healthinequities. https://bit.ly/4tv2mrz Introduction Lung health starts early in life. There is increasing awareness that lung-function trajectories are shaped by complex interactions of genetic profiles, environmental, and social factors [1]. Many of these risk factors (such as air pollution, access to healthcare and health information, and smoking/vaping) already play a role in early life and cross national borders. The overarching theme of the annual 2025 European Respiratory Society (ERS) Congress was “Respiratory health around the globe”, which covered many urgent topics on paediatric respiratory health. ERS unites over 36 000 respiratory clinicians, scientists and allied healthcare professionals, spanning more than 160 countries worldwide. More than 1 in 3 ERS members are under 40 years old, so-called early career members. Assembly 7 (paediatrics) is a prominent and active ERS assembly, with strong representation across clinical care, translational science, registries, and global health initiatives. It plays a central role in shaping early-life respiratory research priorities, developing paediatric-specific clinical guidance, and fostering research collaborations to improve respiratory health trajectories from infancy through to childhood, adolescence, and beyond. Here, from an early career member perspective, we summarise key messages from the 2025 ERS Congress paediatric sessions and situate them within the current evidence base, providing a call for coordinated research, advocacy, and policy responses (figure 1). Multi-faceted approach to paediatric respiratory disease prevention using educational programmes, public awareness, advocacy, and close collaboration. The evolving epidemic of youth vaping Early prevention of chronic respiratory disease requires urgent attention to modifiable exposures, notably tobacco and emerging nicotine products. This important topic was addressed both during a pre-congress webinar [2] and during a symposium on the Paediatric Forum. It is the second year our assembly had the opportunity to organise a paediatric forum, and we included three mini-symposia addressing some of the hottest topics in paediatric respiratory medicine. It was very popular and saw a total audience (in person and online) of approximately 800 individuals. The transition from freebase nicotine to nicotine salt formulations has accelerated addiction among young users. These compounds enable delivery of higher nicotine doses with less irritation, promoting prolonged inhalation and dependence. Scientific evidence supports this mechanism: contemporary pod-based devices (e.g. JUUL) deliver nicotine concentrations of approximately 59 mg·mL−1, equivalent to 20 cigarettes per pod [3]. Adolescents often underestimate nicotine exposure, and surveys show that many users are unaware that their devices contain nicotine [4]. Neurobiological studies confirm that early nicotine exposure disrupts reward pathway maturation, increasing susceptibility to lifelong addiction [5]. Despite extensive prevention efforts, adolescent vaping prevalence continues to rise. Global estimates suggest that ∼17% of youth have ever used e-cigarettes, and ∼5% are current users, with particularly high rates in Europe and North America [6]. Disposable flavoured devices dominate the youth market, leveraging sweet and fruit-based flavours that mask nicotine harshness and reinforce product appeal [7]. Sophie Cohen (Utrecht, the Netherlands) emphasised that vaping alone without prior tobacco exposure can precipitate airway inflammation, macrophage activation, and airflow obstruction, paralleling early COPD pathology. In asthmatic adolescents, vaping may be associated with higher rates of exacerbation and hospitalisation [8]. Chemical analyses demonstrate that e-cigarette aerosols contain volatile carbonyls, metals, and ultrafine particles capable of inducing oxidative stress and epithelial injury [9]. Echoing historic tobacco industry tactics, the nicotine industry markets e-cigarettes as lifestyle accessories to adolescents, despite claims of pursuing a “smoke-free world”. Cohort studies show that youth who vape are three times more likely to initiate cigarette smoking [10], reinforcing concerns that vaping serves as a gateway rather than an off-ramp from tobacco. Neuroimaging and behavioural studies further reveal that adolescent nicotine exposure strengthens dopaminergic reinforcement pathways, cementing dependence [5]. S. Cohen presented the efforts of Dutch healthcare providers to advocate for a national approach [11], integrating a registry for vaping-related complications, education campaigns featuring youth influencers [12], citizen-led petitions exceeding 50 000 signatures, and a 2024 flavour ban that achieved a 20% reduction in youth vaping. This comprehensive framework exemplifies effective multilevel prevention, combining community engagement with legislative action. Alexander Möller (Zurich, Switzerland) highlighted Switzerland's recent law banning all advertisement for or purchase of nicotine-containing products that may reach children and adolescents below the age of 18 years without exemption, underscoring the need for policy parity across product types. Such approaches align with evidence showing that partial restrictions allow market substitution and undermine impact [13]. Beyond bans, effective tobacco control should include age and point-of-sale restrictions, advertising prohibitions, plain packaging, and emission standards limiting toxic aerosol constituents [14, 15]. As a growing global respiratory risk, the vaping pandemic calls for collective, systemic action, especially as today's young users are tomorrow's patients [16]. The importance of the exposome The symposium “Importance of the exposome in prevention and treatment of chronic lung diseases” offered a comprehensive overview of how environmental and lifestyle exposures influence respiratory health throughout life. Ane Johannessen (Bergen, Norway) opened the session by defining the exposome from an epidemiological perspective, referring to Christopher Wild's three domains: the general external (social environment), the specific external (diet, pollutants, chemicals), and the internal (microbiome, inflammation) [17]. She emphasised that the exposome represents the cumulative non-genetic influences on disease across the life course. She highlighted persistent knowledge gaps, especially the scarcity of data from low- and middle-income countries, and stressed the complexity and temporality of exposures. She called for the creation of an “Epi-Exposome Toolbox” to harmonise data and refine analytic methods, a major aim of the new ERS Clinical Research Collaboration (CRC) EXPLAIN-IT (Exposome and Prevention of Lung Diseases, An International Interdisciplinary Translational network) [18]. Erol Gaillard (Leicester, UK) provided insights into the paediatric exposome, describing climate change as a “defining issue” that intensifies air pollution and other environmental threats. Acceleration of extreme weather with increased temperatures means more particulate matter is released, in particular PM2.5 (particulate matter with aerodynamic diameter <2.5 µm), and leads to an increase in concentrations of allergens such as pollens and moulds. He presented systematic review data showing that exposure to traffic-related air pollutants (PM2.5, NO2) contributes directly to the development of childhood asthma, not merely its exacerbation [19]. A 2023 UK report attributed 54 child asthma deaths to pollution levels exceeding World Health Organization guidelines [20]. He also discussed “thunderstorm asthma”, where high pollen and fungal spore count during storms cause sharp rises in emergency admissions, as documented in a 2023 Leicester study [21]. He drew attention to the indoor exposome, noting that warmer, wetter climates foster mould growth, which can have deadly consequences, as illustrated by the UK's “Awaab's Law” [22]. Such exposures are disproportionately prevalent in low- and middle-income countries (LMICs), where inadequate housing, overcrowding, poor ventilation, and limited regulatory oversight can increase cumulative exposure to dampness, mould, and indoor air pollution from biomass fuels. These factors contribute to a higher burden of childhood respiratory diseases, including pneumonia, chronic wheeze, and impaired lung development, reinforcing global health inequities linked to the exposome. Focusing on mechanisms and global mapping, Hsiao-Chi Chuang (Taipei, Taiwan) underscored that 55% of COPD cases occur in non-smokers, emphasising the dominant role of environmental exposures [23]. Using animal models, his team showed that while sustained heat (40°C) or cold (10°C) caused physiological stress, rapid temperature changes between these extremes led to altered gene expression in the airway epithelium [24]. These events were linked to specific gene signatures. This provided a direct molecular connection between climate instability and lung disease. Nikoleta Bizymi (Drafi, Greece) concluded by extending the exposome framework to interstitial lung disease (ILD), challenging the traditional notion of “idiopathic” diagnoses. She explained that the exposome influences lung biology long before symptoms arise. While hypersensitivity pneumonitis is classically exposure-driven, idiopathic pulmonary fibrosis has also been linked to smoking and air pollution, and connective tissue disease-related ILD to silica exposure [25]. She also emphasised the role of the internal exposome, microbiome alterations, and drug exposures in shaping disease progression [26, 27]. Recognising these complex triggers can enable prevention through exposure removal and guide personalised treatment strategies, such as predicting antifibrotic responses. Addressing exposome complexity is the central mission of the CRC EXPLAIN-IT. Chronic lung diseases remain a major respiratory health burden, with the highest impact in socioeconomically deprived populations. The airborne exposome, including pollutants, allergens, and climate-related factors, is a critical driver of these conditions, which often begin early in life and progress silently. The CRC EXPLAIN-IT aims to build an international research infrastructure, identify key research gaps, link existing studies, and explore novel biomarkers to inform guidelines and strengthen global advocacy efforts (see the CRC website for more information: https://europeanlung.org/explainit). The ERS Paediatric Assembly and its early career member members have a key role in advocating the importance of the origins of respiratory disease, often beginning in early life where environmental exposures interact with biological susceptibility. This key interaction plays an integral role in shaping lung and immune development, affecting respiratory health trajectories across the life course. Paediatric rare lung and airway disease Research on rare paediatric lung diseases requires global collaboration. The session “Emerging evidence in paediatric rare lung and airway disease” showcased new high-yield resources, registry-driven evidence, and practical approaches that may advance diagnosis, clinical management, and treatment strategies in primary ciliary dyskinesia (PCD), bronchopulmonary dysplasia (BPD), and childhood ILD (chILD). PCD is a genetic condition affecting motile cilia, resulting in chronic respiratory morbidity and progressive lung disease. In approximately 30%, testing fails to identify a disease-causing gene. Mafalda de Almeida Gomes (London, UK) presented strategies to address negative genetic testing in PCD [28]. The ERS CRC BEAT-PCD, in collaboration with ClinGen (a National Institutes of Health-funded Clinical Genome Resource), established the Motile Ciliopathy Gene Curation Expert Panel (GCEP) to systematically evaluate PCD gene–disease relationships. Using a standardised evidence-based framework, the GCEP has now curated 72 genes, with 34 PCD-associated genes classified as having strong or definitive evidence, while several others have been classified as moderate, limited or disputed; classifications continue to be updated as new evidence emerges. They also developed the CiliaVar database to link PCD-related variants to genotype–phenotype correlations. Astrid Vermaut (Nossegem, Belgium) discussed small airway disease in PCD in comparison with cystic fibrosis (CF) [29]. High-resolution computed tomography and micro-computed tomography of explanted lungs showed extensive small airway loss in PCD, similar to CF, with more proximal bronchial dilatation and greater small airway collapse due to mucus, highlighting the need for disease-specific therapies. Given the known inflammatory effects of particulate matter (PM10 and PM2.5), Ayyüce Ünlü (Ankara, Turkey) studied the impact of air pollution on pulmonary function in children with PCD. 33 PCD patients (>6 years) underwent lung function testing at baseline and after 6 months [30]. No significant correlation was found between pollution exposure and forced expiratory volume in 1 s, but the researchers stress the need for larger, long-term studies. BPD is a chronic lung disease of prematurity with lasting respiratory impact. Burak Uslu (Dresden, Germany) presented results of the TRIBOR randomised, double-blind, placebo-controlled crossover study on the safety and efficacy of tiotropium in children aged 6–12 years with BPD [31]. In a cohort of 23 children, the study team reported no safety issues and they observed some improvement in lung function parameters. chILD comprises a heterogeneous group of over 200 rare diffuse lung diseases, with persistent challenges in diagnosis, limited evidence on long-term progression and lack of evidence of therapeutic options. Pia Maier (Hannover, Germany) presented the largest study of transbronchial cryobiopsy in children to date, assessing its safety and diagnostic yield for chILD diagnosis when genetic testing is inconclusive [32]. 96 bronchoscopies (284 biopsies) were performed in patients aged 22 days to 20.3 years (median 8.9 years) with suspected chILD, or post-lung transplantation, using laryngeal mask airway to maximise airway diameter for intervention. The median procedure time was 31 min. Pneumothorax and oxygen desaturations below 80% occurred in 3.1%, and bleeding requiring intervention in 16.7%, which was managed with measures such as reinflation of the bronchial blocker balloon or application of cold saline or terlipressin. The overall diagnostic yield was 95.8%, confirming transbronchial cryobiopsy as a safe intervention with excellent diagnostic yield that has the potential to improve chILD diagnosis and surveillance both post-transplant and for chILD [33]. Julie Mazenq (Plan de Cuques, France) presented the largest multicentre retrospective study of paediatric post-infectious bronchiolitis obliterans from the French RespiRare cohort, involving 147 patients diagnosed between 2017 and 2023. The majority of children were under 2 years of age at diagnosis and had been hospitalised earlier for an infection that was subsequently identified as the initial event. An infectious trigger was identified in about two-thirds of cases, most commonly adenovirus (28%) and respiratory syncytial virus (26%). Management included inhaled corticosteroids (>90%), azithromycin (59%), and corticosteroid pulse therapy in severe cases (41%) [34]. Using data from the Dutch chILD registry, Simone Hashimoto (Amsterdam, the Netherlands) reported on the association between chILD onset and lung function trajectories across different chILD entities [35]. The study team aimed to understand trajectories of lung function (improvement, stabilisation, or progression) across age. They concluded that patients with early-onset disease before 2 years of age demonstrate worse long-term outcomes, highlighting the need for early recognition and prompt diagnosis and management strategies. This cohort was stratified based on age at disease onset, and chILD comprises a heterogeneous group of underlying conditions, raising the possibility that more severe phenotypes are detected earlier and therefore exhibit worse lung function trajectories. Honorata Marczak (Warsaw, Poland) analysed data of countries participating in the CRC chILD-EU on long-term outcomes of persistent tachypnoea of infancy (PTI)/neuroendocrine cell hyperplasia of infancy (NEHI) [36]. The longitudinal data from 185 patients showed that most children became symptom-free by 4 years of age, although some had crackles or hypoxaemia into adolescence. No differences were found in tachypnoea, retractions, hypoxaemia, or crackles between steroid-treated and untreated children, supporting a steroid-sparing approach. In contrast to PTI/NEHI, bi-allelic ABCA3 mutations cause severe, progressive chILD. Nadia Nathan (Paris, France) reported results from the RespiRare cohort predicting CF transmembrane conductance regulator (CFTR) modulator responsiveness in 44 ABCA3 variants from 37 children through in silico analysis [37]. Variants were classified as non-eligible, undefined, or highly eligible based on amino acid homology and Food and Drug Administration criteria. Most patients (59%) were highly eligible, 6% were non-eligible, and 35% undefined. These results indicate that repurposing CFTR modulators could be a promising therapeutic strategy for most children with ABCA3 deficiency. This session underscored the vital importance of global collaboration in rare paediatric lung diseases, where small patient numbers and uneven resources across the globe make coordinated networks and registries essential. Global disparities of neonatal and infant respiratory diseases The symposium “Global burden of neonatal and infants' respiratory diseases” started with a very powerful patient testimony in collaboration with the European Lung Foundation from Joseph Youngman and his wife Doreen Masika (Kasese, Uganda). They talked about the journey of two of their preterm-born children who experienced respiratory distress. It highlighted the many psychological and financial challenges that families experience in low-resource settings when seeking care for infants with respiratory disease. Maneesh Batra (Seattle, WA, USA) showed that every year ∼4.8 million children under the age of 5 years die, of which 3.6 million are infants younger than 1 year. Of the latter group, 2.3 million are newborns (<1 month old) [38]. The mortality rates are highest in sub-Saharan Africa. Root causes, such as poverty and malnutrition, influence the risk of disease-related mortality. A major part of neonatal mortality is due to preterm birth [39]. The majority of preterm births are actually mild-to-moderate preterm births, but there are not enough continuous positive airway pressure (CPAP) devices for babies who need them [40]. There remains a strong need to improve the care of preterm babies who suffer from respiratory distress, especially where resources are scarce [41]. It is not merely the lack of life-saving resources in LMICs, but also the need for support, training and a workforce that is able to look after preterm babies [42], advocated Refiloe Masekela (Durban, South Africa). As an example, she mentioned a randomised controlled trial in Malawi comparing bubble CPAP to nasal oxygen in children with severe pneumonia. The intervention was nurse-led with no physician oversight, and interim analyses showed that there was excess mortality in the bubble CPAP arm [43], indicating that the presence of technology alone does not improve paediatric outcomes. This was also underlined by Viraraghavan Vadakkencherry Ramaswamy (Hyderabad, India) who reported that CPAP could be lifesaving in infants in respiratory distress, but accurate embedding of this healthcare technology is crucial [44, 45]. Working conditions and payment of the work force is critical, as well as accurate equipment maintenance. Ambrose Agweyu (Nairobi, Kenya) addressed equity-based preparedness and response actions to paediatric respiratory infections. He explained the difference between equality (treating everyone the same) and equity (providing resources based on individual needs). Children who experience deprivation in early life are more likely to face lifelong health problems, educational problems, and limited economic opportunities. In LMICs only 30% of patients needing oxygen for acute care receive it; in sub-Saharan Africa, it is just 9% [46]. Child survival remains fragile, especially since the abrupt reduction of health programmes may diminish decades of progress in this area. He advocated the need for national action to expand domestic financing for health, prioritisation of pro-poor resource allocation, and global solidarity. Conclusion Early career professionals play a vital role in advancing respiratory child health by leading innovative research, promoting evidence-based policies, and actively engaging in advocacy [47]. Many inspirational sessions at the 2025 ERS Congress showed that our collective voice helps raise awareness of issues such as youth vaping, environmental exposures, and the need for global collaboration. By working together across borders and disciplines, we can contribute to improve respiratory health for children worldwide.